Evidence map›Paper›PMID 39173603›Full record

Trial reportPublic health genomics2024

Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized Trial.

Christopher Grisham, Beth N Peshkin, Lia Sorgen, Claudine Isaacs, Mary Kathleen Ladd, Aryana Jacobs, Savannah Binion, Mara Tynan, Emily Kuchinsky, Susan Friedman and 5 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Public health genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Christopher GrishamGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Beth N PeshkinGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Lia SorgenGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Claudine IsaacsGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Mary Kathleen LaddGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Aryana JacobsGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Savannah BinionGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Mara TynanGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Emily KuchinskyMedstar Franklin Square Hospital, Baltimore, Maryland, USA.
Susan FriedmanFORCE: Facing Our Risk of Cancer Empowered, Tampa, Florida, USA.
Kathryn L TaylorGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Kristi GravesGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Suzanne O'NeillGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
David KimGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Marc D SchwartzGeorgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
Genetic Testing For Men From Hereditary Cancer FamiliesR21CA185808 · NCI · GEORGETOWN UNIVERSITY · PI SCHWARTZ, MARC D · 2015 to 2016
$372k
NCI NIH HHS P30 CA051008NCI NIH HHS R21 CA185808
6 · The paper itself

Abstract

introductionWhen a pathogenic BRCA1 or BRCA2 mutation is identified in a family, cascade genetic testing of family members is recommended since the results may inform screening or treatment decisions in men and women. However, rates of cascade testing are low, and men are considerably less likely than women to pursue cascade testing. To facilitate cascade testing in men, we designed a Web-based genetic education tool that addressed barriers to cascade testing, was individually tailored, delivered proactively, and could be used in lieu of pretest genetic counseling to streamline the cascade testing process.

methodsWe randomized 63 untested men from hereditary cancer families to Web-based genetic education (WGE) versus enhanced usual care (EUC). WGE participants were provided access to a genetic education website after which they could accept or decline genetic testing or opt for pretest genetic counseling. EUC participants received an informational brochure and a letter informing them of their eligibility for genetic testing and recommending they schedule genetic counseling. The primary outcome was the uptake of genetic testing.

resultsMen in the WGE group were more likely to complete genetic counseling and/or genetic testing (43% vs. 12.1%; χ2 [n = 63, df = 1] = 7.77, p = 0.005). WGE participants were also more likely to complete genetic testing compared to men in the EUC group (30% vs. 9.1%; χ2 [n = 63, df = 1] = 4.46, p = 0.03).

conclusionThis preliminary trial suggests that a streamlined approach to genetic testing using proactively delivered genetic education may reduce barriers to cascade testing for at-risk men, leading to increased uptake. These results should be interpreted cautiously given the select sample and high rate of non-response.

Indexed as

Genetic CounselingGenetic TestingHereditary Breast and Ovarian Cancer SyndromePatient Education as TopicAdultAgedBRCA1 ProteinBRCA2 ProteinFemaleGenetic Predisposition to DiseaseHumansMiddle AgedMutationOvarian NeoplasmsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1BRCA2Cascade testingGenetic counselingGenetic testingProstate cancer riskTraceback testing

Identifiers

PMID39173603
PMCPMC11407795

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.